2-Deoxy-2-Fluoro-1,3,5-Tri-O-Benzoyl-D-Ribofuranose

97614-43-2

Chenglian Pharmaceutical is an innovative high-tech pharmaceuti cal enterprise that is market-oriented and realizes ♥industrial development through R&D innovation and technoβlogy transformation.

key word:

Pharmaceutical innovative

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large heal÷th industry finance platform company integrating pharmaceutical, intelligent₩ medical, bio pharmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucaulπt reaction, nitration reaction, sulfonation reaction, hydrogenation reaction, f↕luorination reaction, chlorination reaction, brominati♣on reaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. ↑In October 2006, Sitagliptin phosphate Januvia was approved by FDA as the fir★st DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The characteristics of← this drug are that it can stimulate insulin secretion whilσe reducing hunger without causing weight gain. Hypoglycemia and edema will not occur, anγd it is suitable for diabetic patients with poor blood glucose control and frequent hypoglycemi≠a.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterp♣rise that is market-oriented and realizes industrial development through R&D i‍nnovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important pro ducts for the treatment of arthritis. It is well toleraπted and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotrie™ne receptor antagonists. In clinical application, it has good therapeutic effect on atop∞ic asthma and other types of bronchial asthma, and the​ market prospect is huge. In the major category of asth>ma drugs, leukotriene receptor antagonists have the fast♠est growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise t↕hat is market-oriented and realizes industrial development through R&D innovation anλd technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approv☆ed by FDA for Alzheimer's disease in the United States. £Its treatment reaches the target dose and has low toxic and side effects. It has& been widely recognized by our medical community, aβnd good tolerance is its biggest advantage. In October 1999, D↔onepezil was launched in China under the trade name "Aricept", which is the main chemical drug ag€ainst Alzheimer's disease. At present, CFDA has approved a number of domestic enterprises♠ to produce donepezil preparations, the main dosage forms βare tablets, capsules, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, ∏Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for use in₩ the 27 EU member states. The world's first drug approved t≥o prevent venous thromboembolism (VTE) in adult pati ents undergoing elective hip or knee replacement. From June 2019 to June 2020, the ‌annual sales of apixaban products overseas reached about $15.4 billio✘n, with a year-on-year growth of nearly 32%, and the API consumption reached about 23,φ960 kg, with a year-on-year growth of about 28%. Compared wi≈th its main competitor, Rivaroxaban, the drug's annual overseas sa♠les are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpri₹se that is market-oriented and realizes industrial ±development through R&D innovation and technology transλformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and ma✔nufactured by Genzyme. On December 29, 2004, it was approv"ed by FDA for the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) i®n children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaγceutical enterprise that is market-oriented and realizes i©ndustrial development through R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working ♠days). If you need other services, E-mail: 2880705932@qq.com
Union Pharmaceuticals

Follow WeChat

Anhui Union Pharmaceuticals Technology Co., Ltd.

Service line:

+86-21-54285906
E-mail：2880705932@qq.com
Add：4th Floor, Building B3, Creative Industry Park, Hefei, Anhui&n'bsp;P.  R. China.

Copyright © 2022 Anhui Union Pharmaceuticals Technolo gy Co., Ltd.